PhRMA Continues Critique of ICER Drug Pricing Studies

The Pharmaceutical Research and manufacturers of America (PhRMA) have repeatedly spoken out against the cost-effectiveness studies published by the Institute for Clinical and Economic Review (ICER) and has recently publicized its own four pointed list of recommendations to ICER. Read more here. (Source: Joe Cantlupe, BioPharma DIVE, 9/29/16)

You might also be interested in:

ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
McKesson’s Sarah Alwardt Expands on HEOR, Value of RWE April 4, 2018
ICER Announces New Program to Boost Transparency March 31, 2018
eDossier System to Offer hēRo3 Model Integration November 8, 2018
ICER Provides Policy Recommendations for Opioid Use Disorder Therapies December 3, 2018
The Utility of ICER Reports for Private Payer Drug Coverage… September 19, 2018
ICER Releases Report on Therapies for Long-term Prophylaxis HAE November 16, 2018